164 related articles for article (PubMed ID: 12182035)
21. A dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction.
Traino AC; Di Martino F
Phys Med Biol; 2006 Dec; 51(24):6449-56. PubMed ID: 17148828
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies.
Garsi JP; Schlumberger M; Rubino C; Ricard M; Labbé M; Ceccarelli C; Schvartz C; Henri-Amar M; Bardet S; de Vathaire F
J Nucl Med; 2008 May; 49(5):845-52. PubMed ID: 18413399
[TBL] [Abstract][Full Text] [Related]
23. Radiation dose to the upper spine from therapeutic administrations of iodine-131-sodium iodide.
Stabin MG
J Nucl Med; 1993 Apr; 34(4):695-6. PubMed ID: 8455090
[TBL] [Abstract][Full Text] [Related]
24. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research.
Sarlis NJ
Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):103-15. PubMed ID: 12476792
[TBL] [Abstract][Full Text] [Related]
25. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
Menzel C; Kranert WT; Döbert N; Diehl M; Fietz T; Hamscho N; Berner U; Grünwald F
J Nucl Med; 2003 Jul; 44(7):1065-8. PubMed ID: 12843221
[TBL] [Abstract][Full Text] [Related]
26. [Stunning in radioiodine therapy of benign thyroid disease. Quantification and therapeutic relevance].
Krohn T; Meyer PT; Ocklenburg C; Knollmann D; Nowak B; Schaefer WM
Nuklearmedizin; 2008; 47(6):248-54. PubMed ID: 19057798
[TBL] [Abstract][Full Text] [Related]
27. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
28. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
29. Patterns of relapse following radiotherapy for differentiated thyroid cancer: implication for target volume delineation.
Azrif M; Slevin NJ; Sykes AJ; Swindell R; Yap BK
Radiother Oncol; 2008 Oct; 89(1):105-13. PubMed ID: 18579244
[TBL] [Abstract][Full Text] [Related]
30. Planning of 131I therapy for graves disease based on the radiation dose to thyroid follicular cells.
Eterovic D; Antunovic Z; Markovic V; Grosev D
J Nucl Med; 2008 Dec; 49(12):2026-30. PubMed ID: 18997041
[TBL] [Abstract][Full Text] [Related]
31. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
Pahlka RB; Sonnad JR
Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
[TBL] [Abstract][Full Text] [Related]
32. Radiation dose to patients and relatives incident to 131I therapy.
Zanzonico PB
Thyroid; 1997 Apr; 7(2):199-204. PubMed ID: 9133684
[TBL] [Abstract][Full Text] [Related]
33. Radioiodine treatment for malignant thyroid disease.
Berg G
Acta Oncol; 2006; 45(8):1041-5. PubMed ID: 17118836
[TBL] [Abstract][Full Text] [Related]
34. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
35. [Combined radioiodine (I131) treatment and radio-guided surgery for recurrent cervical well-differentiated thyroid cancer].
Schachter P; Shimonov M; Lorberboim M
Harefuah; 2005 Mar; 144(3):168-72, 232, 231. PubMed ID: 15844454
[TBL] [Abstract][Full Text] [Related]
36. 131I ablation treatment in young females after the Chernobyl accident.
Travis CC; Stabin MG
J Nucl Med; 2006 Oct; 47(10):1723-7. PubMed ID: 17015910
[TBL] [Abstract][Full Text] [Related]
37. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of tracer studies for 131I treatment in hyperthyroid cats.
Broome MR; Turrel JM; Hays MT
Am J Vet Res; 1988 Feb; 49(2):193-7. PubMed ID: 3348530
[TBL] [Abstract][Full Text] [Related]
39. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice.
Biermann M; Pixberg MK; Dörr U; Dietlein M; Schlemmer H; Grimm J; Zajic T; Nestle U; Ladner S; Sepehr-Rezai S; Rosenbaum S; Puskás C; Fostitsch P; Heinecke A; Schuck A; Willich N; Schmid KW; Dralle H; Schober O;
Nuklearmedizin; 2005; 44(6):229-34, 236-7. PubMed ID: 16400382
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy.
Willegaignon J; Stabin MG; Guimarães MI; Malvestiti LF; Sapienza MT; Maroni M; Sordi GM
Health Phys; 2006 Aug; 91(2):123-7. PubMed ID: 16832193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]